HR+/HER2− breast cancer constitutes approximately 65–75% of all breast cancer cases worldwide. Although CDK4/6 inhibitors have substantially extended progression-free survival (PFS), up…
IntroductionCircadian regulation in cancer biologyThe promise and challenges of cancer chronotherapyThe future of circadian medicine in cancer careReferencesFurther…